Skip to content

We conduct intense LDL-C lowering therapy for patients with asymptomatic cervical internal carotid stenosis and evaluate signal change of carotid plaque on MRI-VISTA

We conduct intense LDL-C lowering therapy for patients with asymptomatic cervical internal carotid stenosis and evaluate signal change of carotid plaque on MRI-VISTA - Study of intense lipid-lowering effect on carotid MRI signal change

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000028006
Enrollment
10
Registered
2017-07-01
Start date
2017-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical internal carotid artery stenosis

Interventions

anti-PCSK9 antibody, subcutaneous, once per two weeks, for 6months

Sponsors

Hyogo Brain and Heart Center at Himeji
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients must meet all of the following inclusion criteria 1. Asymptomatic patients with cervical internal carotid artery stenosis of 40 to 79% stenosis 2. Patients who do not achieve the LDL-C target value on the guidelines, despite taking statin with the maximum tolerated dose approved in Japan for more than 3 months

Exclusion criteria

Exclusion criteria: Patients who meet any of the following exclusion criteria 1. Patients with symptomatic cervical internal carotid artery stenosis 2. Patients with serious renal impairment 3. Patients with hepatic dysfunction 4. MRI incompatible patients

Design outcomes

Primary

MeasureTime frame
Signal change rate from baseline of carotid plaque on MRI-VISTA at 1 month, 2 months, 3 months, 6 months after the start of intense LDL-C lowering therapy

Secondary

MeasureTime frame
Parameter change of carotid plaque by carotid ultrasound

Countries

Japan

Contacts

Public ContactYoshikazu Fukuda

Hyogo Brain and Heart Center at Himeji Department of General Affairs

yoshikazu_fukuda@pref.hyogo.lg.jp+81-79-293-3131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026